Summit Therapeutics Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2017 to 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Summit Therapeutics Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2017 to 2023.
  • Summit Therapeutics Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$56.3M, a 165% decline year-over-year.
  • Summit Therapeutics Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$197M, a 67.1% increase year-over-year.
  • Summit Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$615M, a 681% decline from 2022.
  • Summit Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$78.8M, a 11.1% increase from 2021.
  • Summit Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$88.6M, a 68.1% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$615M -$536M -681% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-20
2022 -$78.8M +$9.82M +11.1% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-20
2021 -$88.6M -$35.9M -68.1% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-09
2020 -$52.7M -$23.6M -80.9% Jan 1, 2020 Dec 31, 2020 10-K/A 2022-12-21
2019 -$29.1M -$40M -368% Feb 1, 2019 Dec 31, 2019 10-K 2021-03-31
2018 $10.9M +$37.2M Feb 1, 2018 Jan 31, 2019 10-K 2021-03-31
2017 -$26.4M Feb 1, 2017 Jan 31, 2018 8-K 2020-09-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.